

1 **Characteristics of COVID-19 fatality cases in East Kalimantan, Indonesia**

2
3 **Swandari Paramita* , Ronny Isnwardana, Krispinus Duma, Rahmat Bakhtiar, Muhammad**

4 **Khairul Nuryanto, Riries Choiru Pramulia Yudia, Evi Fitriany, Meiliati Aminyoto**

5 Department of Community Medicine, Faculty of Medicine, Mulawarman University,

6 Samarinda, East Kalimantan, Indonesia

7
8 *Corresponding Author: s.paramita@fk.unmul.ac.id

9 10 **Abstract**

11 ***Introduction***

12 Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection. On March 2, 2020,
13 Indonesia announced the first confirmed cases of COVID-19 infection. East Kalimantan will
14 play an important role as the new capital of Indonesia. There is attention to the preparedness
15 of East Kalimantan to respond to COVID-19. We report the characteristics of COVID-19 fatality
16 cases in here.

17 ***Methods***

18 We retrospectively analyzed the fatality cases of COVID-19 patients from the East Kalimantan
19 Health Office information system. All patients were confirmed COVID-19 by RT-PCR
20 examination.

21 ***Results***

22 By July 31, 2020, 31 fatality cases of patients had been identified as having confirmed COVID-
23 19 in East Kalimantan. The mean age of the patients was 55.1 ± 9.2 years. Most of the patients
24 were men (22 [71.0%]) with age more than 60 years old (14 [45.2%]). Balikpapan has the
25 highest number of COVID-19 fatality cases from all regencies. Hypertension was the most
26 comorbidities in the fatality cases of COVID-19 patients in East Kalimantan.

27 ***Discussion***

28 Older age and comorbidities still contributed to the fatality cases of COVID-19 patients in East
29 Kalimantan, Indonesia. Hypertension, diabetes, cardiovascular disease, and cerebrovascular
30 disease were underlying conditions for increasing the risk of COVID-19 getting into a serious
31 condition.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

32 **Conclusion**

33 Active surveillance for people older than 60 years old and having underlying diseases is
34 needed for reducing the case fatality rate of COVID-19 in East Kalimantan.

35 **Keywords**

36 Comorbidity, fatality cases, COVID-19, Indonesia

37

38 **Introduction**

39 Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection (1). In the past, there
40 have been two epidemics of coronavirus, namely Severe Acute Respiratory Syndrome (SARS)
41 (2), with a mortality rate of 10% (3) and Middle East Respiratory Syndrome (MERS) (4), with
42 a mortality rate of 37% (5).

43 On March 11, 2020, the World Health Organization (WHO) announced the COVID-19 as
44 a pandemic (6). During March 2020, the new major epidemic center of COVID-19 infection
45 has been identified in Asia, Middle East, Europe, and North America. The number of
46 confirmed cases of COVID-18 outside China had increased rapidly (7). Until July 31, 2020, the
47 USA, Brazil, and India were the countries for the most COVID-19 cases in the world. There are
48 more than 17 million confirmed cases worldwide (8).

49 On March 2, 2020, President Joko Widodo announced the first confirmed cases of
50 COVID-19 infection in Indonesia (9). On March 18, 2020, the first patient of COVID-19 in East
51 Kalimantan was a patient from Abdul Wahab Sjahranie Hospital Samarinda, the main referral
52 hospital in East Kalimantan for COVID-19 (10). East Kalimantan will play a significant role as
53 the new capital of Indonesia. There is attention to the preparedness of East Kalimantan to
54 respond to COVID-19 (11). As of July 31, 2020, the province has reached 1,426 confirmed
55 cases with 31 deaths (12). Therefore, the study aims to describe the characteristics of fatality
56 cases of COVID-19 patients in East Kalimantan.

57

58 **Methods**

59 **Study Design**

60 This study was a descriptive analysis of all fatality cases of COVID-19 patients in East
61 Kalimantan, Indonesia as of the end of July 31, 2020. This study was approved by the Ethical
62 Health Research Commission of Faculty of Medicine Mulawarman University, Samarinda, East
63 Kalimantan, Indonesia. All data were handled to protect patient privacy.

64 **Data Source**

65 All data collected from COVID-19 fatality case records in the East Kalimantan Health
66 Office information system through July 31, 2020. All cases were included with no sampling
67 was done and no eligibility criteria were used.

68 **Variables**

69 The database of patients was collected at the time of entry into the East Kalimantan
70 Health Office information system. All confirmed cases were diagnosed based on reverse
71 transcription-polymerase chain reaction (RT-PCR) examination to confirm COVID-19
72 according to guidelines from the Ministry of Health of the Republic of Indonesia.

73 **Analysis**

74 For all cases, characteristics of patients were summarized using descriptive statistics.
75 Continuous variables were described as a mean and standard deviation; categorical variables
76 were described as number (%). Statistical analyses were done using Microsoft Excel.

77

78 **Results**

79 By July 31, 2020, 31 fatality cases of COVID-19 patients had been identified as having
80 laboratory-confirmed. The highest fatality cases were reaching 24 patients in July 2020. This
81 number has rapidly increased from the last month (Figure 1). Most of the patients were men
82 (22 [71.0%]) with age more than 60 years old (14 [45.2%]). The mean age of the patients was
83 55.1 ± 9.2 years. Balikpapan has the highest number of COVID-19 fatality cases patients (14
84 [45.2%]), but Bontang has the highest case fatality rate (4.3%) from all regencies (Table 1).
85 Hypertension was the most comorbidities in the fatality cases of COVID-19 patients in East
86 Kalimantan. Hypertension, diabetes, cardiovascular disease, and cerebrovascular disease
87 were the most common underlying conditions for the fatality cases of COVID-19 patients.
88 There were 9 (29%) patients have more than one comorbidity (Table 2).

89

90

91

92

93

94

95

96 **Table 1. Characteristics of COVID-19 fatality cases**

97

Characteristics	Mean ± SD or N (%)
Age, years	55.1 ± 9.2
30-39 years	2 (6.5%)
40-49 years	6 (19.4%)
50-59 years	9 (29.0%)
60-69 years	13 (41.9%)
>69 years	1 (3.2%)
Sex	
Men	22 (71.0%)
Women	9 (29.0%)
Hospital admission of patients	
Province Hospital	15 (48.4%)
Regency Hospital	9 (29.0%)
Private Hospital	7 (22.6%)
Origin of patients	
Balikpapan City	14 (45.2%)
Samarinda City	11 (35.5%)
Paser Regency	2 (6.5%)
Other regencies in East Kalimantan	4 (12.9%)
CFR (Case Fatality Rate)	
East Kalimantan Province	2.2%
Bontang City	4.4%
Samarinda City	3.6%
Balikpapan City	2.8%
Berau Regency	1.3%
East Kutai Regency	1.0%
Kutai Kartanegara Regency	0.4%

98

99


100 **Table 2. Comorbidities of COVID-19 fatality cases**

101

Comorbidities	
Hypertension	9 (29.0%)
Diabetes	7 (22.6%)
Cardiovascular disease	6 (19.4%)
Cerebrovascular disease	5 (16.1%)
Other comorbidities	4 (12.9%)
Number of comorbidites	
1 comorbidity	22 (71.0%)
>1 comorbidities	9 (29.0%)

102

103



104

105

106 Figure 1. The number of COVID-19 fatality cases in East Kalimantan (March to July 2020)

107

108

109

110

111 Discussion

112 This study reports the characteristics of 31 fatality cases of COVID-19 patients in East
113 Kalimantan, Indonesia. As of July 31, 2020, there have been 1,426 COVID-19 positive cases in
114 East Kalimantan (12). On that date, there are 108,376 positive confirmed cases of COVID-19,
115 with 65,907 people recovering and 5,131 patients have died in Indonesia (13).

116 The progress of COVID-19 cases in March 2020 in East Kalimantan showed a total case
117 fatality rate (CFR) of 1.85% (11). There was only one fatality case of COVID-19 patients in
118 Samarinda in June 2020 (14). But there were already 10 fatality cases in Samarinda in July
119 2020. The WHO estimates that 14% of infected cases are severe and require hospitalization.
120 Five percent of infected cases are very severe and require intensive care admission, mostly
121 for ventilation with 4% of the infected die. COVID-19 pandemic may cause the death of 6% of
122 the global population (15).

123 The mean age of the dying patients in this study was 55.1 ± 9.2 years and 14 (45.2%)
124 fatality case patients with age more than 60 years old. These results are similar to the previous
125 retrospective cohort study in Indonesia. Data from the majority of the fatality cases, older
126 people were associated with an increased risk of death (16). This is consistent with a study
127 about the mortality rate of COVID-19 with a median age of 56.0 years. In-hospital death was
128 associated with older age on admission (17).

129 The majority of fatality cases of COVID-19 patients in East Kalimantan are male (22
130 [71.0%]). This is consistent with a meta-analysis study which showed that men took the
131 largest percentage in the distribution of COVID-19 according to gender (18). These results
132 are similar to the previous study at Abdul Wahab Sjahranie Hospital Samarinda which showed
133 that most patients were also male (10).

134 Hospital admission of 15 (48.4%) fatality case patients were in province hospital. There
135 are 16 main referral hospitals for COVID-19 in East Kalimantan. Abdul Wahab Sjahranie
136 Hospital in Samarinda and Kanujoso Djatiwibowo Hospital in Balikpapan are two of province
137 hospitals in East Kalimantan. Province hospitals have more medical equipment needed for
138 COVID-19 patients in critical condition, compared with regency or private hospitals (12).

139 The highest number of COVID-19 fatality case patients (14 [45.2%]) were in Balikpapan,
140 but Bontang has the highest case fatality rate (4.3%) from all regencies. East Kalimantan has
141 been assigned as the new capital of the Republic of Indonesia. The flow of people who came
142 in and out of this province has increased recently. Balikpapan, Samarinda, and Bontang are

143 three regencies with the highest population density in East Kalimantan (11). The spread of
144 COVID-19 depends on high population densities. Controlling infection rates is key to COVID-
145 19 control and it depends on population densities (19).

146 Hypertension, diabetes, cardiovascular disease, and cerebrovascular disease were the
147 most common underlying conditions for the fatality case of COVID-19 patients. There were 9
148 (29%) patients have more than one comorbidity. These results are similar to systematic
149 review and meta-analysis study which showed that comorbidities are risk factors for severe
150 COVID-19 patients. The most prevalent comorbidities were hypertension and diabetes,
151 followed by cardiovascular disease (20). This is also consistent with a meta-analysis study
152 which showed that hypertension, diabetes, cardiovascular disease, and cerebrovascular
153 disease were risk factors associated with COVID-19 patients (21). These results are similar to
154 the previous study at Wuhan, China which showed that underlying hypertension was
155 significantly associated with severe COVID-19 on hospital admission. Hyperglycemia in
156 diabetes was associated with death in patients with severe COVID-19 in Wuhan, China (22).

157

158 **Conclusion**

159 Patients with older age and comorbidities need observation and early intervention to
160 prevent the development of serious COVID-19 conditions. Active surveillance for people older
161 than 60 years old and having underlying diseases is needed for reducing the case fatality rate
162 of COVID-19 in East Kalimantan.

163

164 **REFERENCES**

- 165 1. Richman D, Whitley R, Hayden F. *Clinical Virology*. 4th ed. Washington: ASM Press;
166 2016.
- 167 2. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, Becker S, et al.
168 Identification of a novel coronavirus in patients with severe acute respiratory
169 syndrome. *N Engl J Med*. 2003;348(20):1967–76.
- 170 3. WHO. Summary of probable SARS cases with onset of illness from 1 November 2002 to
171 31 July 2003. World Health Organization. 2003.
- 172 4. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a
173 novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med*.
174 2012;367(19):1814–20.

- 175 5. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). World Health
176 Organization. 2019.
- 177 6. WHO. Novel Coronavirus – China. World Health Organization. 2020.
- 178 7. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19:
179 towards controlling of a pandemic. *Lancet*. 2020;395(10229):1015–8.
- 180 8. Worldometer. COVID-19 Coronavirus Pandemic. Worldometer. 2020.
- 181 9. Djalante R, Lassa J, Setiamarga D, Mahfud C, Sudjatma A, Indrawan M, et al. Review
182 and analysis of current responses to COVID-19 in Indonesia: Period of January to March
183 2020. *Prog Disaster Sci*. 2020;100091.
- 184 10. Paramita S, Isnuwardana R, Marwan M, Alfian DI, Masjhoer DH. Clinical features of
185 COVID-19 patients in Abdul Wahab Sjahranie Hospital, Samarinda, Indonesia. *medRxiv*.
186 2020;
- 187 11. Paramita S, Rahmadi A, Isnuwardana R, Nugroho RA. One-month Progress of COVID-19
188 Cases in East Kalimantan, Indonesia. *Open Access Maced J Med Sci*. 2020;8(T1):45–50.
- 189 12. Dinas Kesehatan Provinsi Kalimantan Timur. Dinas Kesehatan Provinsi Kalimantan
190 Timur [Internet]. COVID-19. 2020. Available from: <https://covid19.kaltimprov.go.id>
- 191 13. Kementerian Kesehatan RI. Situasi Terkini Perkembangan Coronavirus Disease (COVID-
192 19). Kementerian Kesehatan RI. 2020.
- 193 14. Paramita S, Isnuwardana R, Rahmadi A, Rafshodia O, Kusasih I. Epidemiological
194 characteristics of COVID-19 patients in Samarinda, East Kalimantan, Indonesia.
195 *medRxiv*. 2020;
- 196 15. Grech V. Unknown unknowns–COVID-19 and potential global mortality. *Early Hum*
197 *Dev*. 2020;144:105026.
- 198 16. Raharusun P, Priambada S, Budiarti C, Agung E, Budi C. Patterns of COVID-19 mortality
199 and vitamin D: an Indonesian study. *SSRN*. 2020;3585561.
- 200 17. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. *Lancet*.
201 2020;395(10229):1014–5.
- 202 18. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical
203 characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol*.
204 2020;92(6):577–83.
- 205 19. Rocklöv J, Sjödin H. High population densities catalyse the spread of COVID-19. *J Travel*
206 *Med*. 2020;27(3):taaa038.

- 207 20. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the
208 novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis.
209 Int J Infect Dis. 2020;
- 210 21. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-
211 19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049.
- 212 22. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in
213 adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8.
214